

Telephone: (202) 721-8200
C3 Fax: (202) 721-8250

Email: wlp@wenderoth.com
Website: www.wenderoth.com
Blog: www.uspatents.org

WENDEROTH LIND & PONACK, L.L.P.

Attorneys & Counselors at Law
Patents, Trademarks & Copyrights

1030 15th Street, N.W., Suite 400 East, Washington, D.C. 20005-1503

Michael R. Davis
Warren M. Cheek
Charles R. Watts
Michael S. Huppert
Jeffrey R. Filipek
W. Douglas Hahn
David M. Ovedovitz
Kenneth W. Fields

Of Counsel:

John T. Miller
Matthew M. Jacob
Nils E. Pedersen

Amy E. Schmid*

Walter C. Pledger

Andrew L. Dunlap

William R. Schmidt*

Mark D. Pratt

Ray Thomas, Jr.

Andrew B. Freistein

Andrew D. St. Clair*

Jeffrey J. Howell

Stephen W. Kopchik*

Paul D. Pyla*

Jon T. Self*

Allen N. Doyel

*Member of a bar other than
D.C., practice is limited to
matters and proceedings
before Federal Courts
and Agencies.

FACSIMILE COVER SHEET

Date: January 19, 2011

To: Examiner Janet L. Epps-Smith, Group Art Unit 1633

Fax: 571-273-0757

From: Jon T. Self, Ph.D.

Number of pages being transmitted, including this cover sheet: 3

Please direct all questions concerning the transmittal of these pages to Jon Self

**RE: Serial No. 10/573,385 (Tomoki HAMAMOTO et al.), filed May 7, 2007,
Confirmation No. 9339**

MESSAGE:

Dear Examiner Epps-Smith

I'm attaching a set of proposed claim amendments for your convenience.

Claim 1 has been amended to incorporate the subject matter of claims 2 and 4 (which are cancelled) and to clarify that the "thus-precipitated CMP-NeuAc has a purity measured by HPLC of 95% or more." I'd like to discuss whether this might overcome the outstanding obviousness rejection.

The remaining amendments put the dependent claims into proper form by reciting "The...".

I will give you a call at 2:30 this afternoon.

Many thanks

CONFIDENTIALITY NOTICE

This message is intended for the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service.

PROPOSED AMENDMENT TO THE CLAIMS

1. (Currently amended) A process for purification of CMP-N-acetylneuraminic acid (CMP-NeuAc) without employment of any chromatography treatment, comprising the following steps (1) to (4):

step (1): a step of adding a calcium ion or a magnesium ion to a CMP-NeuAc-containing solution, thereby causing phosphoric acid, pyrophosphoric acid, and a nucleotide which coexist with CMP-NeuAc to precipitate;

step (2): a step of adding a phosphatase to the CMP-NeuAc-containing solution, thereby converting the nucleotide which coexists with CMP-NeuAc into a nucleoside;

step (3): a step of adding an alcohol having a carbon number of 5 or less, thereby precipitating CMP-NeuAc in the form of salt; and

step (4): a step of collecting the thus-precipitated CMP-NeuAc,

~~wherein steps (1) and (2) are performed in a sequence selected from:~~

~~step (1) and then step (2), or~~

~~step (1) and step (2) performed simultaneously; and wherein these steps are performed in a sequence selected from:~~

~~step (1), step (2), step (3), and then step (4), or~~

~~step (1) and step (2) are performed simultaneously and then steps (3) and (4) are performed sequentially, and~~

wherein the thus-precipitated CMP-NeuAc has a purity measured by HPLC of 95% or more.

2. (Original) A process according to claim 1, wherein these steps are performed in the following sequence: step (1), step (2), step (3), and then step (4).

3. (Cancelled)

4. (Currently amended) A process according to claim 1, wherein step (1) and step (2) are performed simultaneously and then steps (3) and (4) are performed sequentially.

Serial No. 10/573,385
Attorney Docket No. 2006_0434A
DRAFT

5. (Currently amended) A-The process according to claim 1, wherein step (3) and step (4) are performed a plurality of times.

6. (Cancelled)

7. (Currently amended) A-The process according to claim 1, wherein the phosphatase is *Escherichia coli* alkaline phosphatase.

8. (Cancelled)

9. (Currently amended) A-The purification process according to claim 1, wherein the CMP-NeuAc collected in step (4) is subjected to cation exchange reaction for substitution of the cationic moiety of the CMP-NeuAc.

10. (Currently amended) A-The purification process according to claim 9, wherein the cation exchange reaction employs an ion-exchange resin.